A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia.

This study has been completed.

Study NCT00077727 Information provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

First Received: February 11, 2004 Last Updated: March 17, 2008 History of Changes

No Study Results Posted for this Study

Study Status:	This study has been completed.
Study Completion Date:	February 2005
Estimated Primary Completion Date:	No date given